



Publication of the 2008 Annual Report

Paris, April 8, 2009 – BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced that its 2008 Annual Report, in its capacity as Reference Document, was registered with the French Market Authorities on Tuesday, April 7, 2009. It is available free of charge to the public upon request as per current legal regulations at BioAlliance Pharma's headquarters - 49 Boulevard du Général Martial Valin, 75015 Paris - and may be consulted at the <http://www.bioalliancepharma.com> website (under Investors / Publications).

The Reference Document comprises the annual financial report, the report by the Chairman of the Supervisory Board on the Board's activities and on internal controls, the reports from the Auditors and their fees, and the annual information document.

About BioAlliance Pharma

As a preferred partner for hospital-based specialists, BioAlliance Pharma is a specialty biopharmaceutical company which develops and markets innovative products, especially in the fields of opportunistic infections and chemotherapy complications. In areas where medical needs are insufficiently met, our targeted approaches help overcome drug resistance and improve patient health & quality of life. BioAlliance Pharma's ambition is to become a leading European player in these fields by coupling innovation to patient needs.

For more information, visit the BioAlliance Pharma web site at <http://www.bioalliancepharma.com>.

BioAlliance Pharma SA

Dominique Costantini, President and CEO

Tel.: +33 1 45 58 76 01

dominique.costantini@bioalliancepharma.com

Nicolas Fellmann, CFO

Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol

Tel.: +33 6 64 18 99 59

caroline@alizerp.com